CRISPR Therapeutics (CRSP) Stock Forecast, Price Target & Predictions
CRSP Stock Forecast
CRISPR Therapeutics stock forecast is as follows: an average price target of $109.58 (represents a 119.78% upside from CRSP’s last price of $49.86) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
CRSP Price Target
The average price target for CRISPR Therapeutics (CRSP) is $109.58 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $52.00. This represents a potential 119.78% upside from CRSP's last price of $49.86.
CRSP Analyst Ratings
According to 11 Wall Street analysts, CRISPR Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CRSP stock is 0 'Strong Buy' (0.00%), 7 'Buy' (63.64%), 3 'Hold' (27.27%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
CRISPR Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 12, 2024 | Joon Lee | Truist Financial | $100.00 | $46.55 | 114.82% | 100.56% |
| Aug 06, 2024 | Gil Blum | Needham | $84.00 | $50.11 | 67.63% | 68.47% |
| Aug 06, 2024 | Benjamin Burnett | Stifel Nicolaus | $59.00 | $50.01 | 17.98% | 18.33% |
| Aug 06, 2024 | Luca Issi | RBC Capital | $60.00 | $50.13 | 19.70% | 20.34% |
| May 09, 2024 | Jack Allen | Robert W. Baird | $52.00 | $53.29 | -2.42% | 4.29% |
| Nov 23, 2022 | - | Citigroup | $63.00 | $55.72 | 13.07% | 26.35% |
| Aug 09, 2022 | Geulah Livshits | Chardan Capital | $79.30 | $81.39 | -2.57% | 59.05% |
| Jun 17, 2022 | Kostas Biliouris | BMO Capital | $98.00 | $70.73 | 38.56% | 96.55% |
| Apr 28, 2022 | - | Credit Suisse | $78.00 | $51.96 | 50.12% | 56.44% |
| Feb 16, 2022 | Gil Blum | Needham | $170.00 | $61.97 | 174.33% | 240.95% |
The latest CRISPR Therapeutics stock forecast, released on Aug 12, 2024 by Joon Lee from Truist Financial, set a price target of $100.00, which represents a 114.82% increase from the stock price at the time of the forecast ($46.55), and a 100.56% increase from CRSP last price ($49.86).
CRISPR Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 5 |
| Avg Price Target | - | $75.75 | $71.00 |
| Last Closing Price | $49.86 | $49.86 | $49.86 |
| Upside/Downside | -100.00% | 51.93% | 42.40% |
In the current month, the average price target of CRISPR Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CRISPR Therapeutics's last price of $49.86. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Cowen & Co. | Sell | Sell | Hold |
| Aug 06, 2024 | Needham | Buy | Buy | Hold |
| Aug 06, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 18, 2024 | Citigroup | Buy | Buy | Hold |
| Feb 15, 2024 | Wolfe Research | - | Peer Perform | Initialise |
| Dec 11, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Oct 17, 2023 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| Aug 17, 2023 | Citigroup | Neutral | Buy | Upgrade |
| Jun 09, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
CRISPR Therapeutics's last stock rating was published by Cowen & Co. on Aug 06, 2024. The company gave CRSP a "Sell" rating, the same as its previous rate.
CRISPR Therapeutics Financial Forecast
CRISPR Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $70.00M | $100.00M | $6.00K | $94.00K | - | $178.00K | $12.90M | $824.00K | $900.70M | $539.00K | $370.00K | $148.00K | $44.00K | $157.00K | $77.02M | $211.93M |
| Avg Forecast | $517.76K | $517.68K | $517.61K | $517.53K | $38.68M | $31.47M | $21.60M | $14.70M | $30.74M | $7.20M | $12.06M | $23.05M | $140.94M | $11.89M | $1.80M | $25.85M | $7.12M | $1.85M | $2.21M | $2.80M | $2.19M | $1.23M | $900.19M | $1.40M | $2.20M | $1.92M | $18.13M | $3.02M | $45.21M | $6.15M |
| High Forecast | $517.76K | $517.68K | $517.61K | $517.53K | $38.68M | $31.47M | $21.60M | $14.70M | $30.74M | $14.27M | $12.06M | $23.05M | $204.13M | $11.89M | $1.80M | $25.85M | $7.12M | $1.85M | $2.21M | $7.99M | $6.23M | $3.50M | $2.57B | $3.99M | $6.29M | $5.49M | $51.71M | $8.62M | $128.99M | $17.56M |
| Low Forecast | $517.76K | $517.68K | $517.61K | $517.53K | $38.68M | $31.47M | $21.60M | $14.70M | $30.74M | $838.23K | $12.06M | $23.05M | $132.69K | $11.89M | $1.80M | $25.85M | $7.12M | $1.85M | $2.21M | $100.20K | $78.19K | $43.83K | $32.21M | $50.02K | $78.84K | $68.82K | $648.54K | $108.14K | $1.62M | $220.20K |
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 9 | 18 | 15 | 9 | 10 | 16 | 8 | 5 | 6 | 6 | 6 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.89% | 3.87% | 0.00% | 0.05% | - | 0.06% | 5.90% | 0.67% | 1.00% | 0.39% | 0.17% | 0.08% | 0.00% | 0.05% | 1.70% | 34.44% |
CRISPR Therapeutics's average Quarter revenue forecast for Sep 23 based on 18 analysts is $11.89M, with a low forecast of $11.89M, and a high forecast of $11.89M. CRSP's average Quarter revenue forecast represents a -83.02% decrease compared to the company's last Quarter revenue of $70.00M (Jun 23).
CRISPR Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 9 | 18 | 15 | 9 | 10 | 16 | 8 | 5 | 6 | 6 | 6 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-132.41M | $-90.26M | $-64.49M | $-131.54M | $-177.37M | - | $-169.93M | $-137.24M | $-122.42M | $767.02M | $-109.87M | $-104.62M | $-89.90M | $-77.08M | $-67.26M | $31.98M | $139.98M |
| Avg Forecast | $-204.76K | $-204.73K | $-204.70K | $-204.67K | $-15.30M | $-12.45M | $-8.54M | $-5.81M | $-12.16M | $-2.85M | $-4.77M | $-119.21M | $-55.74M | $-4.70M | $-711.80K | $-127.49M | $-2.82M | $-156.70M | $-874.98K | $-136.36M | $-129.35M | $-123.87M | $717.37M | $-106.88M | $-85.67M | $-79.24M | $-48.69M | $-60.86M | $-17.88M | $-2.43M |
| High Forecast | $-204.76K | $-204.73K | $-204.70K | $-204.67K | $-15.30M | $-12.45M | $-8.54M | $-5.81M | $-12.16M | $-331.50K | $-4.77M | $-95.36M | $-52.47K | $-4.70M | $-711.80K | $-101.99M | $-2.82M | $-125.36M | $-874.98K | $-109.08M | $-103.48M | $-99.10M | $860.84M | $-85.51M | $-68.54M | $-63.39M | $-38.95M | $-48.69M | $-639.76K | $-87.08K |
| Low Forecast | $-204.76K | $-204.73K | $-204.70K | $-204.67K | $-15.30M | $-12.45M | $-8.54M | $-5.81M | $-12.16M | $-5.64M | $-4.77M | $-143.05M | $-80.73M | $-4.70M | $-711.80K | $-152.99M | $-2.82M | $-188.04M | $-874.98K | $-163.63M | $-155.22M | $-148.65M | $573.89M | $-128.26M | $-102.81M | $-95.08M | $-58.42M | $-73.03M | $-51.01M | $-6.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.16% | 126.81% | 0.51% | 46.69% | 1.13% | - | 1.25% | 1.06% | 0.99% | 1.07% | 1.03% | 1.22% | 1.13% | 1.58% | 1.11% | -1.79% | -57.52% |
6 analysts predict CRSP's average Quarter EBITDA for Sep 21 to be $-123.87M, with a high of $-99.10M and a low of $-148.65M. This is -116.15% lower than CRISPR Therapeutics's previous annual EBITDA (Jun 21) of $767.02M.
CRISPR Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 9 | 18 | 15 | 9 | 10 | 16 | 8 | 5 | 6 | 6 | 6 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-112.15M | $-77.74M | $-53.06M | $-110.58M | $-174.55M | - | $-179.22M | $-141.25M | $-127.15M | $759.23M | $-113.16M | $-107.04M | $-92.44M | $-79.66M | $-69.73M | $30.54M | $138.42M |
| Avg Forecast | $-68.23M | $-101.15M | $-100.23M | $-108.72M | $-114.33M | $-117.81M | $-120.02M | $-122.78M | $-112.66M | $-120.48M | $-121.22M | $-125.99M | $5.63M | $-168.93M | $-180.65M | $-134.75M | $-191.08M | $-162.75M | $-181.30M | $-144.11M | $-133.13M | $-128.66M | $710.08M | $-110.08M | $-87.65M | $-81.47M | $-50.31M | $-63.09M | $77.23M | $563.89M |
| High Forecast | $-68.23M | $-101.15M | $-100.23M | $-108.72M | $-114.33M | $-117.81M | $-120.02M | $-122.78M | $-112.66M | $-83.09M | $-121.22M | $-100.79M | $29.14M | $-63.24M | $-180.65M | $-107.80M | $-191.08M | $-130.20M | $-181.30M | $-115.29M | $-106.50M | $-102.93M | $852.09M | $-88.07M | $-70.12M | $-65.18M | $-40.25M | $-50.47M | $92.67M | $676.67M |
| Low Forecast | $-68.23M | $-101.15M | $-100.23M | $-108.72M | $-114.33M | $-117.81M | $-120.02M | $-122.78M | $-112.66M | $-152.05M | $-121.22M | $-151.18M | $-14.08M | $-205.32M | $-180.65M | $-161.69M | $-191.08M | $-195.30M | $-181.30M | $-172.94M | $-159.76M | $-154.39M | $568.06M | $-132.10M | $-105.18M | $-97.77M | $-60.37M | $-75.71M | $61.78M | $451.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.43% | 0.39% | 0.58% | 1.07% | - | 1.24% | 1.06% | 0.99% | 1.07% | 1.03% | 1.22% | 1.13% | 1.58% | 1.11% | 0.40% | 0.25% |
CRISPR Therapeutics's average Quarter net income forecast for Sep 21 is $-128.66M, with a range of $-154.39M to $-102.93M. CRSP's average Quarter net income forecast represents a -116.95% decrease compared to the company's last Quarter net income of $759.23M (Jun 21).
CRISPR Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 9 | 18 | 15 | 9 | 10 | 16 | 8 | 5 | 6 | 6 | 6 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $18.29M | $19.03M | $22.36M | $21.17M | $27.00M | - | $28.02M | $24.13M | $24.35M | $29.81M | $24.52M | $25.77M | $21.54M | $21.35M | $19.55M | $17.27M | $15.52M |
| Avg Forecast | $41.21M | $41.21M | $41.20M | $41.19M | $3.08B | $2.51B | $1.72B | $1.17B | $2.45B | $573.45M | $959.60M | $19.70M | $11.22B | $946.38M | $143.27M | $21.07M | $567.01M | $147.05M | $176.11M | $222.90M | $173.95M | $97.51M | $27.88M | $111.27M | $175.38M | $153.09M | $13.49M | $240.56M | $43.67M | $489.86M |
| High Forecast | $41.21M | $41.21M | $41.20M | $41.19M | $3.08B | $2.51B | $1.72B | $1.17B | $2.45B | $1.14B | $959.60M | $23.64M | $16.25B | $946.38M | $143.27M | $25.28M | $567.01M | $147.05M | $176.11M | $635.97M | $496.29M | $278.20M | $33.45M | $317.47M | $500.38M | $436.79M | $16.18M | $686.36M | $52.41M | $1.40B |
| Low Forecast | $41.21M | $41.21M | $41.20M | $41.19M | $3.08B | $2.51B | $1.72B | $1.17B | $2.45B | $66.72M | $959.60M | $15.76M | $10.56M | $946.38M | $143.27M | $16.85M | $567.01M | $147.05M | $176.11M | $7.98M | $6.22M | $3.49M | $22.30M | $3.98M | $6.28M | $5.48M | $10.79M | $8.61M | $34.94M | $17.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.02% | 0.13% | 1.06% | 0.04% | 0.18% | - | 0.13% | 0.14% | 0.25% | 1.07% | 0.22% | 0.15% | 0.14% | 1.58% | 0.08% | 0.40% | 0.03% |
CRISPR Therapeutics's average Quarter SG&A projection for Dec 23 is $11.22B, based on 9 Wall Street analysts, with a range of $10.56M to $16.25B. The forecast indicates a 61235.87% rise compared to CRSP last annual SG&A of $18.29M (Sep 23).
CRISPR Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 9 | 18 | 15 | 9 | 10 | 16 | 8 | 5 | 6 | 6 | 6 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.41 | $-0.98 | $-0.67 | $-1.41 | $-2.24 | - | $-2.32 | $-1.84 | $-1.67 | $10.01 | $-1.51 | $-1.53 | $-1.32 | $-1.30 | $-1.15 | $0.53 | $2.52 |
| Avg Forecast | $-0.80 | $-1.19 | $-1.18 | $-1.28 | $-1.35 | $-1.39 | $-1.41 | $-1.45 | $-1.33 | $-1.42 | $-1.43 | $-1.36 | $0.07 | $-1.99 | $-2.13 | $-1.74 | $-2.25 | $-2.28 | $-2.22 | $-1.94 | $-1.76 | $-1.75 | $3.52 | $-1.47 | $-1.27 | $-1.18 | $-0.95 | $-1.06 | $-0.56 | $-0.46 |
| High Forecast | $-0.80 | $-1.19 | $-1.18 | $-1.28 | $-1.35 | $-1.39 | $-1.41 | $-1.45 | $-1.33 | $-0.98 | $-1.43 | $-1.36 | $0.34 | $-0.74 | $-2.13 | $-1.74 | $-2.25 | $-2.28 | $-2.22 | $0.49 | $0.45 | $0.44 | $12.01 | $0.37 | $0.32 | $0.30 | $0.24 | $0.27 | $0.14 | $0.12 |
| Low Forecast | $-0.80 | $-1.19 | $-1.18 | $-1.28 | $-1.35 | $-1.39 | $-1.41 | $-1.45 | $-1.33 | $-1.79 | $-1.43 | $-1.36 | $-0.17 | $-2.42 | $-2.13 | $-1.74 | $-2.25 | $-2.28 | $-2.22 | $-6.61 | $-6.01 | $-5.98 | $-0.89 | $-5.02 | $-4.34 | $-4.04 | $-3.24 | $-3.60 | $-1.92 | $-1.56 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.71% | 0.46% | 0.38% | 0.63% | 0.98% | - | 1.20% | 1.04% | 0.95% | 2.84% | 1.03% | 1.20% | 1.11% | 1.37% | 1.09% | -0.94% | -5.52% |
According to 6 Wall Street analysts, CRISPR Therapeutics's projected average Quarter EPS for Sep 21 is $-1.75, with a low estimate of $-5.98 and a high estimate of $0.44. This represents a -117.51% decrease compared to CRSP previous annual EPS of $10.01 (Jun 21).
CRISPR Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.70 | $70.00 | 9900.00% | Buy |
| FATE | Fate Therapeutics | $4.00 | $39.75 | 893.75% | Buy |
| NTLA | Intellia Therapeutics | $22.55 | $119.16 | 428.43% | Buy |
| EDIT | Editas Medicine | $3.86 | $17.00 | 340.41% | Buy |
| VERV | Verve Therapeutics | $5.39 | $21.50 | 298.89% | Buy |
| BEAM | Beam Therapeutics | $25.58 | $64.20 | 150.98% | Buy |
| CRSP | CRISPR Therapeutics | $49.87 | $109.58 | 119.73% | Buy |
| CRBU | Caribou Biosciences | $2.10 | $3.00 | 42.86% | Buy |
| SRPT | Sarepta Therapeutics | $125.69 | $169.93 | 35.20% | Buy |
| NVO | Novo Nordisk | $132.00 | $159.00 | 20.45% | Buy |
| KRYS | Krystal Biotech | $189.26 | $191.00 | 0.92% | Buy |
| REGN | Regeneron Pharmaceuticals | $1.15K | $952.23 | -16.96% | Buy |
CRSP Forecast FAQ
Is CRISPR Therapeutics a good buy?
Yes, according to 11 Wall Street analysts, CRISPR Therapeutics (CRSP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 63.64% of CRSP's total ratings.
What is CRSP's price target?
CRISPR Therapeutics (CRSP) average price target is $109.58 with a range of $52 to $180, implying a 119.78% from its last price of $49.86. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CRISPR Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CRSP stock, the company can go up by 119.78% (from the last price of $49.86 to the average price target of $109.58), up by 261.01% based on the highest stock price target, and up by 4.29% based on the lowest stock price target.
Can CRISPR Therapeutics stock reach $70?
CRSP's average twelve months analyst stock price target of $109.58 supports the claim that CRISPR Therapeutics can reach $70 in the near future.
What are CRISPR Therapeutics's analysts' financial forecasts?
CRISPR Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $106.45M (high $106.45M, low $106.45M), average EBITDA is $-42.099M (high $-42.099M, low $-42.099M), average net income is $-475M (high $-475M, low $-475M), average SG&A $8.47B (high $8.47B, low $8.47B), and average EPS is $-5.593 (high $-5.593, low $-5.593). CRSP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.07M (high $2.07M, low $2.07M), average EBITDA is $-819K (high $-819K, low $-819K), average net income is $-378M (high $-378M, low $-378M), average SG&A $164.82M (high $164.82M, low $164.82M), and average EPS is $-4.455 (high $-4.455, low $-4.455).
Did the CRSP's actual financial results beat the analysts' financial forecasts?
Based on CRISPR Therapeutics's last annual report (Dec 2022), the company's revenue was $436K, which missed the average analysts forecast of $13.98M by -96.88%. Apple's EBITDA was $-673M, beating the average prediction of $-297M by 126.85%. The company's net income was $-650M, missing the average estimation of $-679M by -4.28%. Apple's SG&A was $102.46M, missing the average forecast of $1.11B by -90.79%. Lastly, the company's EPS was $-8.36, missing the average prediction of $-8.684 by -3.73%. In terms of the last quarterly report (Jun 2023), CRISPR Therapeutics's revenue was $70M, beating the average analysts' forecast of $1.8M by 3789.13%. The company's EBITDA was $-90.262M, beating the average prediction of $-712K by 12580.76%. CRISPR Therapeutics's net income was $-77.74M, missing the average estimation of $-181M by -56.97%. The company's SG&A was $19.03M, missing the average forecast of $143.27M by -86.72%. Lastly, the company's EPS was $-0.98, missing the average prediction of $-2.127 by -53.93%